ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions
Jump to:  View All • a b c [d] e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: 2309
    Damage Accrual Predicts the Development of Lymphoma in Primary Sjogren’s Syndrome
  • Abstract Number: 0286
    Damage Associated with Disease-Specific Effects and Diagnostic or Therapeutic Procedures Is Highly Prevalent in IgG4-Related Disease
  • Abstract Number: 0128
    Damage Index in Patients with Thrombotic Antiphospholipid Syndrome (DIAPS) Version 2.0: One Single Center Pilot Study
  • Abstract Number: L16
    Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial
  • Abstract Number: 2430
    Dapirolizumab Pegol Impacts Important Immunologic Pathways in Systemic Lupus Erythematosus: Pharmacodynamic Analysis of T Cell and Antigen Presenting Cell Pathways from a Phase 2b Trial
  • Abstract Number: 1073
    Dashboard Utilization and Order Menu Revision Improve HLA-B*5801 Testing Prior to Allopurinol Initiation in High-Risk Patients in a Veteran-based Primary Care Setting
  • Abstract Number: 0657
    Data-driven Bayesian Network Analysis for Predicting Difficult-to-treat (DTT) Lupus Nephritis
  • Abstract Number: 0084
    DB-2304, an Immunomodulatory Antibody‒drug Conjugate (ADC) Targeting BDCA2, Displays Strong In Vivo Efficacy in Pharmacodynamic and Psoriasis Models
  • Abstract Number: 0941
    DC-9476, a Novel Selective BRD4(BD2) Inhibitor, Improves Arthritis Scores in Preclinical Models of Rheumatoid Arthritis by Regulating Key Inflammatory Pathways
  • Abstract Number: 2534
    Deciphering Complement-dependent Macrophage Phenotypes in Human Rheumatoid Arthritis Using Combined Computational-experimental Single-cell Omics
  • Abstract Number: 0869
    Deciphering Pathogenic Phenotypes by Multi-modal Deep Single-cell Blood Immunophenotyping in Individuals At-risk for Rheumatoid Arthritis
  • Abstract Number: 2629
    Deciphering Salivary Gland Inflammation in Sjögren’s Syndrome Reveals Shared and Autoantibody-Specific Immune Cell Heterogeneity
  • Abstract Number: 1783
    Deciphering the Roles of Mitochondrial-Related Genes and Ferroptosis in Systemic Lupus Erythematosus: Integrated Analysis for Diagnostic Biomarker Identification and Therapeutic Insights
  • Abstract Number: 1333
    Deciphering Variation in Real-World Early RA Outcomes: A Longitudinal Analysis of the Canadian Early Arthritis Cohort (CATCH) Study
  • Abstract Number: 2306
    Deconstruction and Reconstruction of Sjögren’s Disease: AMP®-AIM Partnership
  • Abstract Number: 1570
    Deconvolution of the Lipidomic Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: Lipid Biomarker Features That Predict Disease Progression in Skin and Lung
  • Abstract Number: 0780
    Deep B Cell Tissue Depletion Following Anti-CD19 CART Cells Therapy
  • Abstract Number: 0921
    Deep Immunologic Profiling of Trisomy 8-associated Autoinflammatory Disease (TRIAD)
  • Abstract Number: 2107
    Deep Immunophenotyping of Knee Osteoarthritis Patients Reveals Alterations in T Cell, Treg, and Monocyte Subpopulations
  • Abstract Number: 1705
    Deep Phenotyping Characterization of Peripheral Natural Killer Cells Reveals Impaired Cytotoxicity and Exhaustion During VEXAS Syndrome
  • Abstract Number: 0444
    Deep Serologic Profiling Identifies Novel Autoantibodies Associated with Fetal Atrioventricular Block
  • Abstract Number: 2307
    Deep Spatial Profiling Unveils Dominant Double Negative B Cells in Severe Forms of Sjögren’s Syndrome
  • Abstract Number: 0036
    Deep Topic Modeling Deconvolves Cell States in Spatial Transcriptomic Profiles of Rheumatoid Arthritis Synovial Tissue
  • Abstract Number: 1141
    Defining a Novel Type of Myositis: Immune Mediated Megaconial Myopathy (IMMM)
  • Abstract Number: 2282
    Defining a Personalized Treatment Approach to Rheumatoid Arthritis: Using Genetic Markers of TNFi Response
  • Abstract Number: 0874
    Defining a Protective Role for Mucosal-associated Invariant T (MAIT) Cells in Spontaneous Cutaneous Lupus Erythematosus
  • Abstract Number: 0818
    Defining BASDAI Cut-offs for Disease Activity States in Axial Spondylarthritis – Results from the EuroSpA Collaboration
  • Abstract Number: 2649
    Defining Clinical Subgroups of Patients with Relapsing Polychondritis: A Latent Class and Decision Tree Analysis in Two Independent Prospective Cohorts
  • Abstract Number: 2638
    Defining Sonographic Enthesitis in Psoriatic Arthritis: Developing a Data- and Expert-driven Diagnostic Criteria for Inflammatory Enthesitis at the Single Enthesis Level
  • Abstract Number: 0904
    Defining the Function of Disease Variants with CRISPR Editing and Multimodal Single Cell Sequencing
  • Abstract Number: 0406
    Delayed Diagnosis and Accrual of Joint Damage in Incident Cases of Juvenile Idiopathic Arthritis
  • Abstract Number: 0639
    Delayed Diagnosis in Systemic Lupus Erythematosus
  • Abstract Number: 0199
    Delivery of Guideline Concordant Care in Childhood-Onset Lupus Nephritis
  • Abstract Number: 0269
    Delphi Survey to Establish Consensus on the OMERACT Core Domain Set for Long-Term Studies of Calcium Pyrophosphate Deposition Disease
  • Abstract Number: 0136
    Demographic and Clinical Characteristics of Patients with SLE Across 5 Registries – the LupusNet Federated Data Network
  • Abstract Number: 2055
    Demographic and Ocular Characteristics of Scleritis Patients with Systemic Rheumatologic Disease in the IRIS® Registry (Intelligent Research in Sight)
  • Abstract Number: 1606
    Demographic and Treatment Patterns in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Cohort Analysis of US Claims and Clinical Data
  • Abstract Number: 2393
    Demographic Differences in Trends of Systemic Lupus Erythematosus In-hospital Patient Outcomes
  • Abstract Number: 1007
    Demographic, Social, and Disease Factors Associated with Interstitial Lung Disease and Disease-Related Death in Dermatomyositis
  • Abstract Number: 2256
    Depletion of Citrullinated Vimentin-reactive Follicular Helper T Cells with Treatment-induced Remission of Recent-onset Rheumatoid Arthritis When Compared to Non-remission at 6 Months
  • Abstract Number: 0130
    Depression Genetic Risk, Diagnoses, and Treatments in Association with Cardiovascular Disease Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in the All of Us Research Program
  • Abstract Number: 1002
    Depression Screening in Patients with Rheumatologic Diseases in a Large Tertiary Care Center
  • Abstract Number: 0347
    Dermato-polymyositis Mortality in U.S. Population: Declining Cancer and Cardiovascular Diseases Among the Leading Underlying Causes of Death over Two Decades
  • Abstract Number: 0437
    Describing Maternal Outcomes Among Veterans with a History of Systemic Lupus Erythematosus and Rheumatoid Arthritis
  • Abstract Number: 2499
    Description of Patients with Kawasaki Disease Shock Syndrome at a Large Tertiary Center
  • Abstract Number: 2500
    Description of Patients with Refractory Kawasaki Disease at a Large Tertiary Center
  • Abstract Number: 2045
    Descriptive Study on the Use of Serum Levels of Immunoglobulin G4, Immunoglobulin E and Eosinophil Count as Serum Biomarkers Across Four Clinical Phenotypes of IgG4-Related Disease
  • Abstract Number: 1894
    Detection of Fibrotic Lung Changes and Bronchiectasis in RA Patients Screened for Lung Cancer with Low-dose CT Chest: Results from a Large Multi-hospital System
  • Abstract Number: 2566
    Detrimental Effects of Proton Pump Inhibitors on Bone Mineral Density Are Not Mediated by Changes in Serum Calcium or Parathyroid Hormone in Patients with Inflammatory Rheumatic Diseases: A Cross-sectional Study
  • Abstract Number: 0970
    Deubiquitylase (DUB) BRCC36 Isopeptidase Complex (BRISC) Inhibitors Prevent IFNAR1 Deubiquitination to Restore Natural Type I IFN Response in Autoimmunity
  • Abstract Number: 1135
    Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials
  • Abstract Number: 0290
    Deucravacitinib Long-term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program
  • Abstract Number: 2056
    Deucravacitinib Treatment Did Not Impact Immune Response to SARS-CoV-2 Vaccines and Infection in Patients with Plaque Psoriasis: Results from the Phase 3 POETYK Long-Term Extension Trial
  • Abstract Number: 0662
    Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in SLE: Efficacy by Baseline Demographics and Disease Characteristics in the Phase 2 PAISLEY Trial
  • Abstract Number: 1137
    Deucravacitinib, an Oral,Selective,Allosteric Tyrosine Kinase 2 Inhibitor, in Patients WithModerate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (PSORIATYK SCALP)
  • Abstract Number: 1921
    Devastating Morbidity and Mortality Rates in the Hmong Population with a Diagnosis of Gout Who Had a COVID-19 Infection
  • Abstract Number: 2660
    Developing Predictive Models for the Diagnosis of VEXAS Syndrome
  • Abstract Number: 2326
    Development and Evaluation of a Machine Learning Model for the Early Identification of Psoriatic Arthritis
  • Abstract Number: 0796
    Development and Evaluation of Machine Learning Prediction Models for Hospitalizations Due to Opioid-Related Harms Among New Users with Rheumatic and Musculoskeletal Diseases
  • Abstract Number: 0316
    Development and Evaluation of the Adult-onset Still’s Disease Activity Index Based on Whole RNA-seq Analysis: A Novel Approach Independent of Tocilizumab Treatment
  • Abstract Number: 1406
    Development and Functional Characterization of Salivary Gland Organoids to Investigate Sjögren’s Disease
  • Abstract Number: 1255
    Development and Validation of a Brief Measure of Uncertainty Among Patients with Vasculitis and Other Rheumatic Diseases
  • Abstract Number: 2627
    Development and Validation of a Novel Score System to Guide Diagnostic Procedures in Children with Concerns of Chronic Nonbacterial Osteomyelitis
  • Abstract Number: 0368
    Development and Validation of a Patient-centered Self-evaluation Questionnaire in Systemic Lupus Erythematosus: LUPIN®
  • Abstract Number: 1968
    Development and Validation of an Arthritis-Detection Algorithm Using Thermal Imaging in Adults and Children
  • Abstract Number: 2280
    Development of a Blood-based Cell-free DNA Classifier Assay to Predict Biologic and Targeted Synthetic DMARDs Response in Rheumatoid Arthritis Patients (PRIMA-102)
  • Abstract Number: 2160
    Development of a Lupus Chatbot
  • Abstract Number: 2422
    Development of a Multiplexed-engineered, Off-the-shelf CAR NK Cell with Unique Multi-Pathogenic Cell Targeting Capacity for the Treatment of Autoimmune Diseases in the Absence of Conditioning Chemotherapy
  • Abstract Number: 0186
    Development of a Novel Dried Blood Spot Method to Improve Capacity for ANA Testing in Lower-Resource Settings
  • Abstract Number: 1066
    Development of a Pharmacy-Led Intervention to Improve Osteoporosis Screening in VA Community-Based Outpatient Clinics
  • Abstract Number: 0867
    Development of a Remote Patient Monitoring System Based on a Novel Digital Biomarker for Swelling in Rheumatoid Arthritis
  • Abstract Number: 0362
    Development of a Theory-based Digital Messaging Program to Reduce Fatigue in Systemic Lupus Erythematosus
  • Abstract Number: 1179
    Development of an Optimal Physiotherapy Intervention to Reduce Stiffness Following Knee Joint Replacement
  • Abstract Number: 1842
    Development of Next Generation CAR T Cell Therapy for the Off-the-shelf Treatment of Autoimmune Diseases Without Conditioning Chemotherapy
  • Abstract Number: 2558
    Development of Non-genetic Risk Stratification Model of Severe Allopurinol Hypersensitivity Syndrome, a Multicenter Study in Thailand
  • Abstract Number: 1351
    Development of Noninvasive Assessment Technology for Rheumatoid Arthritis Based on Contact Property Measurements
  • Abstract Number: 1287
    Development of the Academy for Workforce Advancement to Enrich Rheumatology Diversity
  • Abstract Number: 2526
    Development of the Hospital Emergency Advocacy & Treatment Kit (HEAT Kit) for Patients with Vasculitis
  • Abstract Number: 1403
    Development, Validation and Clinical Use of Health-Related Behaviour Health Fitness Questionnaire (HR-BHF) in Indian (Asian) Subjects Attending a Community Rheumatology Center
  • Abstract Number: 2648
    Diagnosis of Giant Cell Arteritis by 18F-FDG PET/CT in Patients on Glucocorticoid Therapy: Importance of Delayed Imaging
  • Abstract Number: 2655
    Diagnostic Challenges of Dermatomyositis: A Retrospective Study of Its Dermatologic Mimics and Misdiagnoses
  • Abstract Number: 2089
    Diagnostic Performance of ACR and NICE Criteria for Hip Osteoarthritis
  • Abstract Number: 1517
    Diagnostic Performance of Anti-dsDNA Antibodies in Pleural, Ascitic and Pericardial Fluid for Lupus Serositis: Experience of a Tertiary Center in Mexico
  • Abstract Number: 1516
    Diagnostic Performance of Anti-ribosomal P Antibodies in Cerebrospinal Fluid of Neuropsychiatric Systemic Lupus Erythematosus with Diffuse Central Nervous System Manifestations. Experience in a Tertiary Center in Mexico
  • Abstract Number: 1432
    Diagnostic Performance of Mayor Salivary Gland Ultrasound for Diagnosis of Sjögren’s Syndrome in Routine Clinical Practice
  • Abstract Number: 0701
    Diagnostic Performances of Vascular Biomarkers Soluble Fms-like Tyrosine Kinase (sFlt-1) and Placental Growth Factor (PlGF) in Scleroderma Renal Crisis: A Case Control Study
  • Abstract Number: 0851
    Diagnostic Ultrasound Enthesitis Tool (DUET) for Psoriatic Arthritis: The Distribution of Elementary Lesions Is Influenced by Site
  • Abstract Number: 0012
    Dichotomous Expression of CXCR3 and CCR9 and Relationship to Intestinal Permeability in B Cells in Rheumatoid Arthritis
  • Abstract Number: 1199
    Diclofenac Sodium 1% Gel Improves Physical Function in the Performance of Important Activities of Daily Living in Patients with Hand or Knee Osteoarthritis
  • Abstract Number: 1900
    Dietary Exposures Associated with Incident Spondyloarthritis
  • Abstract Number: 1459
    Dietary Modification and Intermittent Fasting Are Common in Patients with Axial Spondylarthritis and May Lead to Reduced Inflammatory Activity
  • Abstract Number: 1109
    Differences Between Correlation and Causal Inference in Detecting Predictors of Undefined Crystal Arthropathy in Women
  • Abstract Number: 0409
    Differences in Clinical Presentation and Outcomes Between Down Syndrome-Associated Arthritis and Juvenile Idiopathic Arthritis
  • Abstract Number: 1171
    Differences in Microbiome Profiles Based on Pain Severity and Inflammatory Biomarkers in Acute Low Back Pain
  • Abstract Number: 2255
    Differences in Pharmacological Prescription to Patients with Recent-onset Arthritis: Analysis from the Gender Perspective
  • Abstract Number: 2082
    Different Clinical Phenotypes of Patients with Anti-synthetase Syndrome: Unsupervised Cluster Analysis in the CLASS Database
  • Abstract Number: 0762
    Different Giant Cell Arteritis Phenotypes May Present Distinct Types of Ischemic Complications
  • Abstract Number: 0554
    Different Prevalence of Intestinal Inflammation in Radiographic and Non-radiographic Axial Spondyloarthritis. Data from EISER Study
  • Abstract Number: 2169
    Different Trajectories of Patient Reported Outcomes in Patients with RA in a Stable Phase of Disease – an Observational Study
  • Abstract Number: 2304
    Differential Diagnosis of Sjogren’s vs Non-Sjogren’s Dry Eye
  • Abstract Number: 0481
    Differential Effect of Comorbidities on the Clinical Evolution of Early Arthritis by Sex
  • Abstract Number: 1421
    Differential Impact of B-cell Targeted Monotherapy and Combination Regimen on the Peripheral Blood Transcriptome of Adults with Active Sjögren Disease
  • Abstract Number: 2156
    Differential Item Functioning of Inflammatory Back Pain Criteria in US Subpopulations
  • Abstract Number: 1679
    Differential Pharmacodynamic Changes of Circulated Immune Subsets After Treatment with Abatacept or Adalimumab in Patients with ACPA+ Early RA in the AMPLIFIED Study
  • Abstract Number: 2327
    Differential Quantitative Profile of Myeloid Derived Suppressor Cells and Monocyte Subsets Relate to Clinical Phenotype and Disease Activity in Psoriatic Arthritis Patients
  • Abstract Number: 0731
    Differentiating Primary Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis from Secondary Forms
  • Abstract Number: 0219
    Differentiation of Nail Psoriasis from Healthy Nails Using Ultrasound: A Cross-Sectional Study with a Novel Nail Matrix Measurement Technique
  • Abstract Number: 1398
    Difficult to Treat Rheumatoid Arthritis Incidence and Risk Factors in the Early Arthritis UCLouvain Brussels Cohort
  • Abstract Number: 0758
    Difficult to Treat Takayasu Arteritis: Comparative Efficacy of Colchicine and Tofacitinib
  • Abstract Number: 0715
    Diffuse Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Revisited
  • Abstract Number: 2495
    Diffuse Alveolar Hemorrhage in Patient with ANCA-associated Vasculitis AndInterstitial Lung Disease
  • Abstract Number: 0321
    Diffusion Weighted Imaging in Muscle MRI Can Detect Quantitative Improvements in Muscle Edema: A Post-hoc Analyses of the Study of Tofacitinib in Refractory Dermatomyositis
  • Abstract Number: 2157
    Dimensionality of Inflammatory Back Pain Criteria in the US Population
  • Abstract Number: 2155
    Direct Comparison of Sleep Quality and Risk Factors for Poor Sleep Across Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis
  • Abstract Number: 2635
    Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Appropriateness of Rheumatology Referrals and Treatment Outcomes
  • Abstract Number: 2340
    Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Diagnosis Rates, Referral Pathways, and Educational Value of Screening
  • Abstract Number: 2135
    Disability, Functional Limitation, and Use of Anti-fracture Drug Therapies in a Cohort of 3651 U.S. Adults with Osteogenesis Imperfecta
  • Abstract Number: 2112
    Discontinuation and Non-Publication of Osteoporosis Studies: An Observational Analysis of 7,670,624 Patients
  • Abstract Number: 2113
    Discontinuation and Non-publication of Postmenopausal Osteoporosis Clinical Studies: A Cross-sectional Analysis of 345,435 Patients
  • Abstract Number: 0529
    Discontinuation of Targeted Disease-Modifying Antirheumatic Agents in Older Patients with Rheumatoid Arthritis: Retrospective Analysis of Medicare Data
  • Abstract Number: 2279
    Discontinuation Pattern of Glucocorticoids in Patients with Rheumatoid Arthritis Initiating Biologics or Targeted Synthetic DMARDs in Routine Care
  • Abstract Number: 1191
    Discordant Associations Among Chronological and Biological Age with Multi-joint Osteoarthritis and Symptom Burden: The Johnston County Health Study
  • Abstract Number: 1688
    Discovery and Validation of a New Classification of ANA-RMDs That Better Predict Long Term Outcomes Compared to Legacy Diagnoses
  • Abstract Number: 1537
    Discovery of VENT-03: A Novel Clinical cGAS Inhibitor for the Treatment of SLE and Other Autoimmune Diseases
  • Abstract Number: 0041
    Disease Activity and Serological Inflammatory Markers Are Associated with TNF-a and IL-6-Induced Osteoclasts, but Not with RANKL-Induced Osteoclasts in Peripheral Blood Monocytes from Patients with Rheumatoid Arthritis
  • Abstract Number: 0432
    Disease Activity During Pregnancy in Patients with Rheumatoid Arthritis or Spondyloarthritis: Results from the Multicentre Prospective GR2 Study
  • Abstract Number: 0802
    Disease Activity Is Strongly Associated with RA-related Lung Disease and Interstitial Lung Disease in Early RA: Results from a Multicenter, Prospective Cohort Study
  • Abstract Number: 0520
    Disease Duration Differentially Affects the Clinical Efficacy of Biologics and JAK Inhibitors in Rheumatoid Arthritis: The ANSWER Cohort Study
  • Abstract Number: 0556
    Disease Duration, Age and Clinical Features Related to Aortic Valve Sclerosis in Patients with Spondyloarthritis
  • Abstract Number: 1986
    Disease Flare Following Immune Checkpoint Inhibition in Patients with Cancer and Preexisting Vasculitis
  • Abstract Number: 1630
    Disease Manifestations, Diagnostic Findings, and Mortality of 120 Consecutive Patients Suspected of Giant Cell Arteritis – Results from a Hospital GCA Fast-Track Clinic
  • Abstract Number: 1400
    Disease Modifying Anti-rheumatic Drug Use and Association with Survival in Patients with Rheumatoid Arthritis and Newly Diagnosed Lung Cancer
  • Abstract Number: 2450
    Disease Progression in Anti-Centromere Positive Systemic Sclerosis Patients
  • Abstract Number: 1142
    Disease Trajectory in anti-MDA5 Dermatomyositis Patients Presented with Different Stage of Interstitial Lung Disease
  • Abstract Number: 0871
    Disease-associated Central Nervous System Activation Predicts Good Clinical Response to Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis Patients – “The PreCePRA Study”
  • Abstract Number: 1384
    Disease-modifying Antirheumatic Drugs and Risk of Incident Interstitial Lung Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
  • Abstract Number: 0378
    Disparate Disease Activity Outcomes Associated with Demographic Variables in Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry
  • Abstract Number: 0616
    Disparities in Health-Related Quality of Life Among Patients with Systemic Lupus Erythematosus
  • Abstract Number: 1181
    Disparities in Rehabilitation Outcomes After Knee Arthroplasty
  • Abstract Number: 1012
    Disparities in Time to Diagnosis for Radiographic Axial Spondyloarthritis
  • Abstract Number: 1820
    Disruption of Ca2+ Homeostasis and Enhanced Ca2+ Signaling in Scleroderma Fibroblasts Is Due to the Vicious Cycle Formed by Mitochondrial-derived Reactive Oxygen Species, CaMKII, and ER Extrusion Pump RYR2
  • Abstract Number: 0496
    Dissecting Early RA Patient Trajectories Through Time-independent Disease State Identification Identifies Distinct Patterns Dissected by Inflammation in Blood or Joints
  • Abstract Number: 2136
    Distal Radius Correlation with Femur and Lumbar Spine T-scores: A Comprehensive Analysis
  • Abstract Number: L06
    Distinct Cytokine and Cytokine Receptor Expression Patterns Characterize Different Subtypes of Inflammatory Myopathies
  • Abstract Number: 0903
    Distinct Impacts of Mosaic Loss of Chromosome Y and Genetic Risk on the Age of Onset in Patients with Rheumatoid Arthritis
  • Abstract Number: 1099
    Distinct Metabolomic Signatures of Insulinemia and Incident Gout Risk: A Prospective Cohort Study Among Women
  • Abstract Number: 0523
    Distinct Peripheral Blood Immune Cell Sub-population Signatures at Baseline of Tofacitinib or Adalimumab Initiation Are Associated to Clinical Responses at 6 Months
  • Abstract Number: 1856
    Distinct Proliferative and Special Properties of Peripheral Helper T Cells in RA Synovium
  • Abstract Number: 0816
    Distinct Transcript and Protein Dysregulation Patterns in Dermatomyositis and Systemic Lupus Erythematosus
  • Abstract Number: 1818
    Distribution and Morphological Changes of Adventitial Fibroblasts in Healthy and Scleroderma Skin
  • Abstract Number: 1568
    Distribution of Proteinuria in Scleroderma Renal Crisis: A Multi-Center Study
  • Abstract Number: 1773
    Divergent Genetic Architecture in Boys and Girls with NEMO-deleted Exon 5 Autoinflammatory Syndrome (NEMO-NDAS) Implies Role for Wildtype Effector Cells
  • Abstract Number: 1030
    Diversity in Axial Spondyloarthritis Drug Trials: Examining Enrollment by Sex, Race, Ethnicity and Geographic Region
  • Abstract Number: 1371
    DMARD Utilization Pattern in Older Adults with Rheumatoid Arthritis
  • Abstract Number: 1368
    Do CsDMARDs Still Play a Significant Role in Managing Rheumatoid Arthritis in the Current Biologic/JAKI Era? A Prospective Observational Study to Estimate the Extent of Response to Conventional Synthetic DMARDs in RA– Experience from a Tertiary Care Center in South India
  • Abstract Number: 0511
    Do High Rheumatoid Factor Levels Impact Response to Certolizumab Pegol in Patients with Inadequately Controlled Rheumatoid Arthritis? A Post Hoc Analysis of a Phase 3b Trial
  • Abstract Number: 0228
    Do Imaging Tests Have a Role in Predicting Progression to Rheumatoid Arthritis in People with Clinically Suspect Arthralgia? A Systematic Review & Meta-Analysis
  • Abstract Number: 0175
    Do Knee Strength and Pain Relate to Developing Stair Climbing Difficulty for Knee Osteoarthritis?
  • Abstract Number: 2668
    Do Levels of anti-Jo1 Autoantibodies Have a Prognostic Role? Longitudinal Assessment of anti-Jo1 and HisRS Protein Levels in a Cohort of anti-Jo1 Positive Patients with Anti-synthetase Syndrome
  • Abstract Number: 2328
    Do Patients That Develop PsA Before Psoriasis Have Different Disease Outcomes?
  • Abstract Number: 2350
    Do Smoking and Obesity Impact Secukinumab Treatment Outcomes? Real-world Data from 1,202 European Patients with Psoriatic Arthritis
  • Abstract Number: 1782
    DOCK2 Mutations and Hyper-Inflammatory Syndromes
  • Abstract Number: 1331
    Does Refractory Rheumatoid Arthritis Status Matter in Modeling Patient Global Assessment Trajectories over 20 Years in a Large US Registry?
  • Abstract Number: 0721
    Does Serial ANCA Testing Help Predict the Risk of Relapse in Granulomatosis with Polyangiitis? A Single-center Cohort Study
  • Abstract Number: 2318
    Does the Time Interval Between the Onset of Psoriasis and Psoriatic Arthritis Impact Disease Presentation and Outcomes?
  • Abstract Number: 1591
    Domains and Outcome Measures for the Assessment of Digital Vasculopathy and Raynaud Phenomenon in Juvenile Systemic Sclerosis: A Systematic Review
  • Abstract Number: 2431
    DORIS Remission in Patients with SLE Treated with Anifrolumab: Post Hoc Analysis from TULIP-1 and TULIP-2 Trials in Patents with No Reported History of Prior Immunosuppressant Use
  • Abstract Number: 2686
    Dose Escalation Safety Study of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis:Clinical Results and Mechanistic Analysis of Skin and Peripheral Blood Mononuclear Cells
  • Abstract Number: 0972
    Downregulated Fli1 in Scleroderma Myeloid Cells Contributes to Cardiac Fibrosis via a Galectin-3/mTOR Dependent Pathway
  • Abstract Number: 2609
    Drivers of Infliximab Biosimilar Uptake: A Comparative Analysis of New Biosimilar Initiations versus Switching in a National Rheumatology Registry
  • Abstract Number: 1323
    Drug Abuse Screening in Patients Who Fulfill the 2016 Fibromyalgia Criteria
  • Abstract Number: 2347
    Drug Survival in Spondyloarthritis: Anti-IL17 Outperforms Anti-TNF in First Biologic Treatment
  • Abstract Number: 1316
    Dual Therapy with a JAKi and bDMARD in Patients with Standard Treatment Resistant Rheumatic Disease: A Case Series
  • Abstract Number: 2046
    Duration of Disease and Long-term Outcomes in Patients with Difficult-to-treat Recurrent Pericarditis: A Chronic Condition Treated with NSAIDs, Colchicine, Corticosteroids, and Anti-IL-1 Agents
  • Abstract Number: 1727
    Duration of SARS-CoV-2 Viral Shedding After Infection Among Patients with Rheumatic Disease Using Tumor Necrosis Factor Inhibitors or Rituximab
  • Abstract Number: 2138
    DXA-derived 3D Parameters of the Hip Discriminate Prevalent Fragility Fractures in Individuals with Axial Spondyloarthritis
  • Abstract Number: 0897
    Dynamic eQTLs from Activated Human B Cells Suggest Cell-state Dependent Effects for GWAS Risk Variants in BLK
  • Abstract Number: 2669
    Dysferlin Autoantibodies Compromise Sarcolemmal Repair Capacity and Contribute to the Pathogenesis of Idiopathic Immune Myopathies
  • Abstract Number: 1496
    Dysregulated Serum Cytokines in Association with Clinical Manifestations in Patients with Systemic Lupus Erythematosus
  • Abstract Number: 1165
    Dysregulation of Peripheral Blood B-cells Is Associated with Myocarditis in Patients with Idiopathic Inflammatory Myopathies
Jump to:  View All • a b c [d] e f g h i j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology